- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Wealth Planning, Administration, and Disputes
-
July 10, 2020Silicon Valley Attorneys Listed as “Super Lawyers” and “Rising Stars”
-
July 9, 2020Four Robins Kaplan Firm Members Recognized by Minnesota Lawyer
-
July 9, 2020Robins Kaplan Signs Mansfield Rule to Boost Diversity in Leadership
-
July 21, 2020Discovering a Hidden Revenue Stream: Recoveries from Antitrust Class Action Settlements in Economic Downturn
-
August 18, 2020Discovering a Hidden Revenue Stream: Recoveries from Antitrust Class Action Settlements in Economic Downturn
-
September 10, 2020Volunteer Lawyers Network Riverfront Celebration 2020
-
Summer 2020The Brave New World of Virtual Notarization
-
Summer 2020What Could be the Harm? Minnesota's Harmless Error Statute
-
Summer 2020What's a Fiduciary To Do? Considerations for Periods of Uncertainty
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Publications
June 2020
Trade Secrets: Safe as Houses
Christopher Larus, David Prange, Alyssa Bixby-Lawson - Intellectual Property Magazine
June 4, 2020
Explaining the Almost Unexplainable: Preparing and Presenting Source Code Evidence at Trial
David Prange, Benjamen Linden - LegalTech News
May 6, 2020
Hatch-Waxman Litigation Venue Update Post-Google
Kelsey McElveen, Ellen Levish - Bloomberg Law
May 4, 2020
Explaining The Almost Unexplainable: Source Code Evidence At Trial
David Prange, Benjamen Linden - LegalTech News
April 7, 2020
Protecting Confidential Information When Sheltering in Place
David Prange, Chris Larus - Corporate Counsel
Related News
June 15, 2020
March 24, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.